Astria Therapeutics Inc.
(ATXS)
undefined
undefined%
At close: undefined
9.52
0.21%
After-hours Dec 13, 2024, 04:15 PM EST
Company Description
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States.
Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema.
The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021.
Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
Astria Therapeutics Inc.
| Country | United States |
| IPO Date | Jun 25, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 59 |
| CEO | Jill C. Milne Ph.D. |
Contact Details
Address: 100 High Street Boston, Massachusetts United States | |
| Website | https://www.astriatx.com |
Stock Details
| Ticker Symbol | ATXS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001454789 |
| CUSIP Number | 04635X102 |
| ISIN Number | US04635X1028 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jill C. Milne Ph.D. | Co-Founder, Chief Executive Officer, President & Director |
| Benjamin S. Harshbarger J.D. | Chief Legal Officer |
| Noah C. Clauser CPA | Chief Financial Officer & Treasurer |
| Andrea L. Matthews | Chief Business Officer |
| Andrew A. Komjathy | Chief Commercial Officer |
| Dr. Christopher J. Morabito M.D. | Chief Medical Officer |
| John Ruesch | Senior Vice President of Pharmaceutical Sciences & Technical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13D/A | [Amend] Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 08, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |